QQ客服 官方微博 反馈留言

	Proteasome inhibitor/imatinib combinations exert potentiated antileukemia efficacy but not cardiotoxicity in chronic myeloid leukemia (CPCI-S收录)
	Zhou, Guangbiao[1]; Hu, Zheng[1]; Pan, Xiaofen[1]; Liu, Jinglei[1]; Ma, Liyuan[2]; Liu, Xiaoli[3]; Meng, Fanyi[3]; Li, Juan[4]; Chen, Zhu[2]; Chen, Saijuan
会议名称	BLOOD
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/2101489
专题	华南理工大学
作者单位	1.[1]Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Lab Mol Target Based Therapy Canc, Guangzhou, Guangdong, Peoples R China 2.[2]Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, Shanghai 200030, Peoples R China 3.[3]Nanfang Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China 4.[4]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Zhou, Guangbiao[1],Hu, Zheng[1],Pan, Xiaofen[1],等. Proteasome inhibitor/imatinib combinations exert potentiated antileukemia efficacy but not cardiotoxicity in chronic myeloid leukemia (CPCI-S收录)[C]. 见:BLOOD.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。